Our findings provided a novel mechanism of circCRIM1/IGF2BP1-mediated regulation of immune evasion and indicated that circCRIM1 and IGF2BP1 may act as promising immune therapeutic targets for NSCLC. Here, IGF2BP1 is linked to non-small cell lung carcinoma.